NCT03316586 - A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2017

Primary Completion Date

August 30, 2019

Study Completion Date

August 30, 2019

Conditions

Breast Cancer

Interventions

DRUG

Nivolumab

Nivolumab is an experimental antibody drug that may make the immune response more active against cancer.

DRUG

Cabozantinib

Cabozantinib may help to shrink or stabilize breast cancer

Trial Locations (1)

Dana-Farber Cancer Institute, Boston